http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2326808-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07b71571160c289fbf5fc680dfea513f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D- |
| filingDate | 2004-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ce1e026074f0ee338fa1aac4624fcdb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_480dbc5f6b675f6f63442ec4709aba31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_604dfdb20149e4d8d1066652858c2b91 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62fabdf105944213efa611aea9109fe2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f38e9d37708d61283466f452d076bb2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20a7317b7d96a8c46263aa9a71c0072b |
| publicationDate | 2009-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2326808-T3 |
| titleOfInvention | IMIDAZOTRIAZINE COMPOUNDS FOR THE TREATMENT OF CANCER DISEASES. |
| abstract | A compound of formula (I): ** (See formula) ** in which: R1 is alkyl; w is 0 or 1; R11 is H or C1-3 alkyl; Ring A is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl; Ring B is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, 5-13 membered heterocycle and 5-13 membered heteroaryl; a, b, c, f, g and h are the same or different and each is independently 0 or 1; d and j are the same or different and are independently 1 or 2; each R2 is the same or different and is independently selected from the group consisting of alkylene, alkenylene and alkynylene; Y1 and Y2 are the same or different and each is independently selected from the group consisting of -O-, -S (O) q- and -N (R5) -; q is 0, 1 or 2; each R3 and R4 is the same or different and each is independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ph, Het, -COR5, -CSR5, -CO2R5, -COPh, - CO2Ph, -C (O) Het, -C (O) NR5R6, -C (S) NR5R6, -C (= NR5) R6, -C (= NR5) NR5R6, -CR5 = N-OR6, -OR5, - OCOR5, -S (O) pR5, -S (O) 2OH, -S (O) pNR5R6, -NR5R6, -NR5COR6, -NR5CO2R6, -NR5SO2R6, -NO2, -CN, -SCN and -N3; each p is the same or different and is 0, 1 or 2; m and n are the same or different and each one is independently 0, 1, 2, 3, 4 or 5; each R5 and each R6 are the same or different and each is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl; Ph is phenyl optionally substituted with one or more substituents selected from the group consisting of halo, alkyl, -CO2R5, -OR5, -SO2R5, -SO2NR5R6, -NR5R6, -R2- (NR5R6) CO2R5, Het, -R2-Het, -CN and -N3; and Het is a 5-6 membered monocyclic heterocycle or heteroaryl group containing 1, 2 or 3 heteroatoms selected from the group consisting of N, O and S optionally substituted with one or more substituents selected from the group consisting of halo, alkyl, -CO2R5, -C (O) NR5R6, -OR5, -SO2R5, -SO2NR5R6, -NR5R6, oxo, -CN and -N3; or a pharmaceutically acceptable salt or solvate thereof. |
| priorityDate | 2003-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1191.